# TRIP11

Source: https://onco.cc/targets/trip11/  
OnCo record `trip11` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TRIP11 (Thyroid receptor-interacting protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.

## Summary

Is a membrane tether required for vesicle tethering to Golgi. Has an essential role in the maintenance of Golgi structure and function. It is required for efficient anterograde and retrograde trafficking in the early secretory pathway, functioning at both the ER-to-Golgi intermediate compartment (ERGIC) and Golgi complex.

Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.27, affected pathway 0.95, genetic association 0.00, somatic mutation 0.45). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: thyroid hormone receptor interactor 11; Thyroid receptor-interacting protein 11; CEV14; Trip230; GMAP-210; GMAP210
- Tags: cancer-genes-wave
- Symbol: TRIP11
- Class: tumor-suppressor
- Biology: Is a membrane tether required for vesicle tethering to Golgi. Has an essential role in the maintenance of Golgi structure and function. It is required for efficient anterograde and retrograde trafficking in the early secretory pathway, functioning at both the ER-to-Golgi intermediate compartment (ERGIC) and Golgi complex. Binds the ligand binding domain of the thyroid receptor (THRB) in the presence of triiodothyronine and enhances THRB-modulated transcription. Location: Golgi apparatus, cis-Golgi network membrane; Cytoplasm, cytoskeleton; Endoplasmic reticulum-Golgi intermediate compartment membrane (UniProt). Locus 14q32.12 (HGNC).
- Where found: Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:12305: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12305
- UniProt Q15643: https://www.uniprot.org/uniprotkb/Q15643/entry
- NCBI Gene 9321: https://www.ncbi.nlm.nih.gov/gene/9321
- Ensembl ENSG00000100815: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100815

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)

---
JSON: https://onco.cc/api/v1/entities/trip11.json